EMD Millipore Introduces Drypour Packaging System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMD Millipore Introduces Drypour Packaging System



EMD Millipore, the life-science division of Merck KGaA, has introduced the Drypour packaging system, which minimizes caking during transport and storage of hygroscopic salts used in pharmaceutical manufacturing. The system, which consists of a polyethylene drum with a tamper-evident seal, apolyethylene liner with integrated desiccant bags, and a breathable interior Tyvek liner, helps improve operational efficiency by reducing the time and effort needed to break up heavily caked raw materials, according to the company.

The drum and polyethylene liner prevent outside moisture from entering the product. Any water vapor in the product itself can permeate the interior, tear-resistant Tyvek liner, migrate into the outer polyethylene liner and be absorbed by the integrated desiccant. Unlike other packaging systems, the desiccant bags in the Drypour system are fixed to the perforated polyethylene liner, thus preventing contact with the product, so product quality is not compromised, according to the company. For maximum effect, the desiccant bags are mounted in varying places on the liner.

A range of the company's line of Emprove pharmaceutical raw materials is available in the Drypour packaging system. The Drypour system is available in 100-kilogram package sizes and can be moved with common handling devices. The system meets both European Pharmacopoeia and USP requirements.

Source: EMD Millipore

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here